Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer

Fulvestrant 500 mg is standard of care for endocrine therapy‐naive or pretreated women with hormone receptor‐positive (HR+) metastatic breast cancer (MBC). This study was conducted to explore the potential factors and duration of last endocrine therapy as predictors for the efficacy of fulvestrant 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yannan, Li, Yi, Gong, Chengcheng, Xie, Yizhao, Zhang, Jian, Wang, Leiping, Cao, Jun, Tao, Zhonghua, Wang, Biyun, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724295/
https://www.ncbi.nlm.nih.gov/pubmed/33022852
http://dx.doi.org/10.1002/cam4.3491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724295/
https://www.ncbi.nlm.nih.gov/pubmed/33022852
http://dx.doi.org/10.1002/cam4.3491

Ejemplares similares